Long-term effectiveness and safety of lanadelumab in Canadian patients with hereditary angioedema: a subanalysis of the EMPOWER study.
- DOI
- 10.1186/s13223-025-01007-9
- Published
- 2026 Jan 21
- Container
- Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1186/s13223-025-01007-9,
title = {Long-term effectiveness and safety of lanadelumab in Canadian patients with hereditary angioedema: a subanalysis of the EMPOWER study.},
author = {Betschel SD and Chapdelaine H and Gagnon R and Goodyear MD and Keith PK and El-Zoeiby A and Khutoryansky N and Castaner DN},
year = {2026},
journal = {Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology},
doi = {10.1186/s13223-025-01007-9},
url = {https://doi.org/10.1186/s13223-025-01007-9}
}RIS
TY - JOUR TI - Long-term effectiveness and safety of lanadelumab in Canadian patients with hereditary angioedema: a subanalysis of the EMPOWER study. AU - Betschel SD AU - Chapdelaine H AU - Gagnon R AU - Goodyear MD AU - Keith PK AU - El-Zoeiby A AU - Khutoryansky N AU - Castaner DN PY - 2026 JO - Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology DO - 10.1186/s13223-025-01007-9 UR - https://doi.org/10.1186/s13223-025-01007-9 ER -
APA
SD, B., H, C., R, G., MD, G., PK, K., A, E., N, K., & DN, C. (2026). Long-term effectiveness and safety of lanadelumab in Canadian patients with hereditary angioedema: a subanalysis of the EMPOWER study.. Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology. https://doi.org/10.1186/s13223-025-01007-9
Source records
- pubmed · retrieved 2026-09-27T14:35:19.099Z